Skip to content

Neuropathic pain — master index

Last curated: 2026-08-30 · status: audited

The condition in five sentences. Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system, graded as possible, probable or definite according to history, neuroanatomy, sensory signs and confirmatory evidence (Finnerup 2016, PMID 27115670). Population studies suggest 6.9–10% prevalence when validated screening instruments are used, though case ascertainment varies (van Hecke 2014, PMID 24291734). Ectopic activity, altered ion channels, neuroimmune signaling, disinhibition and central sensitization produce heterogeneous combinations of burning, electric-shock pain, allodynia, numbness and evoked pain (Colloca 2017, PMID 28205574; Finnerup 2021, PMID 32584191). First-line medicines—tricyclic antidepressants, SNRIs, gabapentin and pregabalin—help only a minority, and topical therapies are useful for selected peripheral phenotypes (Finnerup 2015, PMID 25575710). The frontier is mechanism-based phenotyping and combination or neuromodulation strategies that improve modest responder rates without importing opioid or device harms (Petersen 2021, PMID 33818600).

Start here: overview.md. Diagnostic path: definition, grading and diagnosissensory phenotypingbiomarkers. Treatment path: pharmacologytopical/interventionalneuromodulation. Etiology path: diabetes, postherpetic/postsurgical, chemotherapy/toxic, and central pain. Frontier: OPEN-QUESTIONS.md.

Pages

File Scope Status
overview.md Definition, burden, mechanisms, phenotypes and treatment map curated
definition-grading-and-diagnosis.md Possible/probable/definite grading, examination and confirmatory tests curated
epidemiology-and-burden.md Population prevalence, disability and condition-specific burden curated
peripheral-mechanisms.md Ectopic firing, channels, neuroma, small fibers and immune interactions curated
central-sensitization-and-plasticity.md Spinal/cortical amplification, disinhibition and maintained pain curated
sensory-phenotyping-and-qst.md Bedside signs, QST, clusters and mechanism inference curated
diabetic-neuropathic-pain.md Distal symmetric neuropathy, metabolic injury and treatment curated
postherpetic-and-postsurgical-pain.md PHN, nerve injury, prevention and localized therapy curated
chemotherapy-and-toxic-neuropathy.md CIPN prevention, treatment and survivorship curated
spinal-cord-and-central-neuropathic-pain.md SCI, stroke, MS and central phenotypes curated
pharmacologic-treatment.md Antidepressants, gabapentinoids, sodium-channel drugs and combinations curated
topical-and-interventional-treatment.md Lidocaine, capsaicin, blocks, ablation and selection curated
neuromodulation.md SCS, DRG stimulation, non-invasive approaches and durability curated
guidelines.md NeuPSIG, EAN/EFIC and national recommendations curated
biomarkers.md QST, skin biopsy, imaging, electrophysiology and molecular candidates curated
clinical-trials-landscape.md Drugs, combinations, devices and mechanism-stratified trials curated
patient-experience-and-advocacy.md Sleep, function, disbelief, access and patient priorities curated
red-flags-and-safety-concerns.md Progressive deficit, myelopathy, cauda equina, toxicity and medication harms curated

Literature layer

Artifact Status
Bibliography audited; 309 unique live-resolved PMIDs
Landmark notes 6 notes
Guideline registry deepened; >25 international/national documents and explicit disagreement map
Statistics deepened; conflicting estimates, effect sizes and confidence intervals retained side by side
Patient voice audited; organization URLs rechecked 2026-08-30

Curation state

This condition was audited on 2026-08-30. All 18 canonical pages passed the separate claim-to-source review and are curated; each remains within the 150–400-line target and carries 28–34 live-resolved PMID references. The trial landscape contains 16 live-reverified NCT records, and the full condition bibliography contains 309 unique PMIDs. No unresolved substantive citation issue or verification flag remains.